Natalie Vokes
Natalie Vokes
Dana Farber Cancer Institute
بريد إلكتروني تم التحقق منه على dfci.harvard.edu
عنوان
عدد مرات الاقتباسات
عدد مرات الاقتباسات
السنة
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis
JW Locasale, AR Grassian, T Melman, CA Lyssiotis, KR Mattaini, AJ Bass, ...
Nature genetics 43 (9), 869-874, 2011
7742011
Tracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells
CA Lewis, SJ Parker, BP Fiske, D McCloskey, DY Gui, CR Green, ...
Molecular cell 55 (2), 253-263, 2014
3142014
Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells
SM Fendt, EL Bell, MA Keibler, BA Olenchock, JR Mayers, TM Wasylenko, ...
Nature communications 4 (1), 1-11, 2013
2232013
Metabolic pathway alterations that support cell proliferation
MG Vander Heiden, SY Lunt, TL Dayton, BP Fiske, WJ Israelsen, ...
Cold Spring Harbor symposia on quantitative biology 76, 325-334, 2011
2222011
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
D Miao, CA Margolis, NI Vokes, D Liu, A Taylor-Weiner, SM Wankowicz, ...
Nature genetics 50 (9), 1271-1281, 2018
1032018
“Should I give you my smoking lecture now or later?” Characterizing emergency physician smoking discussions and cessation counseling
NI Vokes, JM Bailey, KV Rhodes
Annals of emergency medicine 48 (4), 406-414. e7, 2006
342006
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
D Liu, B Schilling, D Liu, A Sucker, E Livingstone, L Jerby-Amon, ...
Nature medicine 25 (12), 1916-1927, 2019
282019
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non–Small-Cell Lung Cancer
NI Vokes, D Liu, B Ricciuti, E Jimenez-Aguilar, H Rizvi, F Dietlein, MX He, ...
JCO precision oncology 3, 1-12, 2019
72019
Toward molecularly driven precision medicine in lung adenocarcinoma
D Liu, NI Vokes, EM Van Allen
Cancer discovery 7 (6), 555-557, 2017
62017
Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).
Z Bakouny, N Vokes, X Gao, A Nassar, S Abou Alaiwi, R Flippot, ...
Journal of Clinical Oncology 37 (15_suppl), 4514-4514, 2019
52019
Tumor evolution: a problem of histocompatibility
NI Vokes, EM Van Allen
Cell 171 (6), 1252-1253, 2017
42017
Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs).
S Abou Alaiwi, A Nassar, Z El Bakouny, JE Berchuck, P Nuzzo, R Flippot, ...
Journal of Clinical Oncology 37 (15_suppl), 103-103, 2019
32019
Inter-test variability in tumor mutational burden (TMB) quantification and identification of TMB thresholds
N Vokes, EJ Alguilar, R Umeton, A Adeni, L Sholl, M Hellmann, H Rizvi, ...
Cancer Research 79 (13 Supplement), 2514-2514, 2019
12019
MA19. 01 Efficacy and Genomic Correlates of Response to Anti-PD1/PD-L1 Blockade in Non-Small Cell Lung Cancers Harboring Targetable Oncogenes
N Vokes, EJ Alguilar, A Adeni, R Umeton, L Sholl, H Rizvi, M Hellmann, ...
Journal of Thoracic Oncology 13 (10), S422, 2018
12018
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (vol 25, pg 1915, 2019)
D Liu, B Schilling, D Liu, A Sucker, E Livingstone, L Jerby-Arnon, ...
NATURE MEDICINE, 2020
2020
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
D Liu, B Schilling, D Liu, A Sucker, E Livingstone, L Jerby-Arnon, ...
Nature Medicine, 1-1, 2020
2020
Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC).
J Luo, C Bandlamudi, B Ricciuti, N Vokes, AJ Schoenfeld, JV Egger, ...
Journal of Clinical Oncology 38 (15_suppl), 9549-9549, 2020
2020
Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status.
B Ricciuti, KC Arbour, JJ Lin, N Vokes, A Vajdi Hoojghan, YY Li, ...
Journal of Clinical Oncology 38 (15_suppl), e15113-e15113, 2020
2020
Clinical characteristics, genomic features, and recurrence risk of early-stage MET exon 14 mutant non-small cell lung cancer (NSCLC).
G Recondo, R Guo, P Cravero, B Ricciuti, C Falcon, N Vokes, MG Kris, ...
Journal of Clinical Oncology 38 (15_suppl), 9042-9042, 2020
2020
Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors
S Abou Alaiwi, AH Nassar, W Xie, Z Bakouny, JE Berchuck, DA Braun, ...
Cancer Immunology Research, 2020
2020
يتعذر على النظام إجراء العملية في الوقت الحالي. عاود المحاولة لاحقًا.
مقالات 1–20